Why the ClearVue (ASX:CPV) share price is plummeting today

The ClearVue Technologies Ltd (ASX: CPV) share price is falling hard today. This comes after the company announced changes to its executive team.

| More on:
Two men react in shock at Evolution share price drop record profit

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ClearVue Technologies Ltd (ASX: CPV) share price is falling today. This comes after the technology company announced changes to its executive team.

At market open, the company's shares kicked off at 31 cents before plummeting to around 26 cents and stabilising momentarily.

At the time of writing, the ClearVue share is down 14.5% to 26.5 cents.

What happened?

ClearVue advised that its interim CEO Kenan Jagger has handed in his resignation notice.

While Mr Jagger serves out his notice period, he will assist in the transition to incoming new management.

In this morning's release, the ClearVue board thanked him for his positive contributions over the last 2 years, in which he served as chief commercial officer before taking the helm as interim CEO. Mr Jagger was recognised in his efforts to improve sales, marketing, and investor relations activity.

The company advised it was pursuing a replacement with extensive experience, in order to continue moving the global ClearVue business forward.

In addition, the chase for a European CEO, as well as sales and marketing specialists in the United States is also ongoing. The company is developing its global roll-out strategy, and is searching for a leadership team in its tier 1 territories.

ClearVue stated it will update the market in the coming weeks with the inclusion of a European CEO, and other key management roles.

About the ClearVue share price

Despite today's decline, the ClearVue share price has performed relatively well over the past 12 months. Up more than 54% in that time, despite the company's shares witnessing a drop in March due to COVID-19.

Falling to an all-time low of 5 cents, the ClearVue share price settled around the mid-teens before moving on an upwards trajectory.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two people shaking hands in the boardroom on a merger.
Share Market News

Champion Iron raises US$100 million for Rana Gruber acquisition

Champion Iron raised US$100 million from La Caisse to fund its acquisition push for Rana Gruber, increasing La Caisse’s stake…

Read more »

Work meeting among a diverse group of colleagues.
Share Market News

Elders appoints René Dedoncker as next CEO in planned succession

Elders appoints René Dedoncker as next CEO, with Mark Allison supporting a well-planned succession until 2027.

Read more »

Woman with gold nuggets on her hand.
Broker Notes

Why this surging ASX 300 gold stock is forecast to keep on giving

A leading broker forecasts more outperformance from this rocketing ASX gold stock.

Read more »

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: Credit Corp, PLS, and ResMed shares

Let's see what Morgans is saying about these shares this week.

Read more »

Man holding out $50 and $100 notes in his hands, symbolising ex dividend.
Dividend Investing

Passive income: How much do you need to invest to make $500 per month?

This is how much you’d need to unlock significant passive income.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the local market today.

Read more »

Scientists working in the laboratory and examining results.
Share Market News

Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights.

Read more »

View of a business man's hand passing a $100 note to another with a bank in the background.
Opinions

3 ASX shares I'd buy with $10,000 today

Here's where I'd put $10,000 right now.

Read more »